Compare Adaptive Biotechnologies Corp (ADPT) vs ProShares UltraPro Short QQQ ETF (SQQQ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs ProShares UltraPro Short QQQ ETF — how do they compare? Adaptive Biotechnologies Corp trades at $20.24 (market cap $3.33B), while ProShares UltraPro Short QQQ ETF trades at $40.31. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, ProShares UltraPro Short QQQ ETF nearer its low. Which is the better fit depends on your goals.
| ADPT | SQQQ | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $22.37 | $97.65 |
52-Week Low | $10.24 | $36.31 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
SQQQ (ProShares UltraPro Short QQQ ETF) declined 4.18% to $38.28, reflecting its bearish inverse leverage strategy against the Nasdaq-100. Technical indicators show a predominantly bearish signal with moving averages indicating strong selling pressure. The ETF's structure as a daily -3x leveraged product creates inherent decay risks, with historical data showing significant long-term value erosion. Recent news highlights concerns about SQQQ's suitability as a long-term investment vehicle.
SQQQ faces structural headwinds from daily reset mechanisms that compound losses in rising markets. While potentially useful for short-term tactical bearish bets, the ETF's design makes it unsuitable for buy-and-hold strategies. Investors seeking Nasdaq-100 exposure should consider the significant risks of value decay and timing sensitivity inherent in leveraged inverse products.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About ProShares UltraPro Short QQQ ETF
SQQQ is a leveraged inverse ETF that seeks daily investment results, before fees and expenses, that correspond to three times the inverse (-3x) of the daily performance of the Nasdaq-100 Index. It is a tactical trading tool designed for sophisticated investors to profit from or hedge against declines in large-cap technology and growth stocks. Due to its daily reset and the effects of compounding, it is intended for short-term use and carries significant risk if held during periods of high market volatility.
Read more on SQQQ →
